DOCSLIB.ORG

Legemiddelforbruket I Norge 2012–2016 Drug Consumption in Norway 2012–2016

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

2017:1 LEGEMIDDELSTATISTIKK EVT STIKKTITTEL INN HER Legemiddelforbruket i Norge 2012–2016 Drug Consumption in Norway 2012–2016 ISSN 1890-9647 Legemiddelforbruket i Norge 2012–2016 Drug Consumption in Norway 2012–2016 Solveig Sakshaug Hanne Strøm Christian Berg Hege Salvesen Blix Irene Litleskare Tove Granum Utgitt av Folkehelseinstituttet / Published by Norwegian Institute of Public Health Området for Psykisk og fysisk helse Avdeling for Legemiddelepidemiologi Mars 2017 Tittel/Title: Legemiddelstatistikk 2017:1 Legemiddelforbruket i Norge 2012-2016/Drug Consumption in Norway 2012-2016 Forfattere/Authors: Solveig Sakshaug (redaktør) Hanne Strøm Christian Berg Hege Salvesen Blix Irene Litleskare Tove Granum Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no/ The report is available as pdf format only and can be downloaded from the www.fhi.no Layout omslag: www.fetetyper.no Kontaktinformasjon/Contact information Folkehelseinstituttet/Norwegian Institute of Public Health P.O.Box 4404 Nydalen N-0403 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN 978-82-8082-826-2 elektronisk utgave Sitering/Citation: Sakshaug, S (red), Legemiddelforbruket i Norge 2012-2016 [Drug Consumption in Norway 2012-2016], Legemiddelstatistikk 2017:1, Oslo: Folkehelseinstituttet, 2017. Tidligere utgaver/Previous editions: 1977: Legemiddelforbruket i Norge 1974 - 1976 1978: Legemiddelforbruket i Norge 1975 - 1977 1980: Legemiddelforbruket i Norge 1975 - 1979 1981: Legemiddelforbruket i Norge 1980 1982: Legemiddelforbruket i Norge 1977 - 1981 1984: Legemiddelforbruket i Norge 1979 - 1983 1985: Legemiddelforbruket i Norge 1984 1986: Legemiddelforbruket i Norge 1981 - 1985 1987: Legemiddelforbruket i Norge 1986 1988: Legemiddelforbruket i Norge 1987 1989: Legemiddelforbruket i Norge 1984 - 1988 1990: Legemiddelforbruket i Norge 1989 1991: Legemiddelforbruket i Norge 1986 - 1990 1992: Legemiddelforbruket i Norge 1991 1993: Legemiddelforbruket i Norge 1988 - 1992 1994: Legemiddelforbruket i Norge 1989 - 1993 1995: Legemiddelforbruket i Norge 1990 - 1994 1996: Legemiddelforbruket i Norge 1991 - 1995 1997: Legemiddelforbruket i Norge 1992 - 1996 1998: Legemiddelforbruket i Norge 1993 - 1997 1999: Legemiddelforbruket i Norge 1994 - 1998 2000: Legemiddelforbruket i Norge 1995 - 1999 2001: Legemiddelforbruket i Norge 1996 - 2000 2002: Legemiddelforbruket i Norge 1997 - 2001 2003: Legemiddelforbruket i Norge 1998 - 2002 2004: Legemiddelforbruket i Norge 1999 - 2003 2005: Legemiddelforbruket i Norge 2000 - 2004 2006: Legemiddelforbruket i Norge 2001 - 2005 2007: Legemiddelforbruket i Norge 2002 - 2006 2008: Legemiddelforbruket i Norge 2003 - 2007 2009: Legemiddelforbruket i Norge 2004 - 2008 2010: Legemiddelforbruket i Norge 2005 - 2009 2011: Legemiddelforbruket i Norge 2006 - 2010 2012: Legemiddelforbruket i Norge 2007 - 2011 2013: Legemiddelforbruket i Norge 2008 - 2012 2014: Legemiddelforbruket i Norge 2009 - 2013 2015: Legemiddelforbruket i Norge 2010 - 2014 2016: Legemiddelforbruket i Norge 2011 - 2015 Forord Preface Rapporten Legemiddelforbruket i Norge har vært The report Drug Consumption in Norway has been utgitt siden 1977. Statistikken er basert på omsetning published annually since 1977. The statistics are av legemidler fra grossister. based on total drug sales from wholsalers. Dette er den 39. utgaven av rapporten, og den er i This is the 39th edition of the report. It is mainly det vesentlige bygget opp som tidligere utgaver. organized according to the previous editions and the Rapporten utgis som en kombinert norsk/engelsk report is published as a combined Norwegian/English versjon. Hovedkapitlene med statistikk for hver ATC edition. The main statistical chapters for each ATC hovedgruppe, er delvis oversatt til engelsk. ATC group are only partly translated into English. ATC koder er angitt foran de enkelte legemiddelnavn for å codes are included for all the substances in order to øke forståelsen for utenlandske lesere. Generelle increase the understanding. The first part of the kommentarer til totalomsetningen finnes i report includes comments to the total drug innledningskapitlet. consumption. Årets utgave omfatter tallmateriale for perioden The present edition includes data for the period 2012-2016 og er basert på data fra alle grossister 2012-2016. The figures are based on sales from all som selger legemidler i Norge og er inklusive salg av drug wholesalers in Norway and include sales of over legemidler til dagligvarehandelen. Alle legemiddel- the counter medicines which are available in non grossister rapporterer månedlig alt salg av legemidler pharmacy outlets. All wholesalers in Norway report til detaljist (f eks apotek og sykehus/sykehjem, total sales of medicines directly to the Norwegian butikk) til Folkehelseinstituttet. Et nasjonalt Institute of Public Health on a monthly basis. A reseptbasert legemiddelregister (Reseptregisteret) er Norwegian Prescription database (NorPD) was from fra januar 2004 etablert ved Folkehelseinstituttet. January 2004 established at the Norwegian Institute Registeret inneholder reseptopplysninger fra alle of Public Health. NorPD includes prescribing apotek om utlevering av legemidler til pasienter, information at the individual patient level from all forskrivere og institusjoner. Registeret gir mer Norwegian pharmacies. NorPD offers more detailed detaljert kunnskap om legemiddelbruken i information about the drug use in the population. befolkningen. Informasjon fra Reseptregisteret er More information regarding the NorPD is available in tilgjengelig i en egen rapport som utgis årlig og på a separate annually report and on www.norpd.no. nettsiden www.reseptregisteret.no. En liste over ATC og DDD endringer foretatt 1. januar A list of ATC and DDD alterations valid from 2017 finnes på s. 91. 1 January 2017 is included on p. 91. Innledningen gir mer informasjon om den statistiske For more information on the statistical presentation of fremstillingen av legemiddelforbruket. Vi vil presisere drug consumption, please confer the introduction. In at det er viktig for forståelsen av det statistiske order to fully understand the statistical material in this materialet at innledningskapitlet leses først. report we recommend reading the introduction. Rapporten utgis kun i elektronisk format. En pdf fil av This report is available in electronic format only. A rapporten kan nedlastes fra følgende nettsider: pdf file can be downloaded from the website: www.legemiddelforbruk.no eller www.fhi.no. http://www.legemiddelforbruk.no/english/ or from Henvendelser vedrørende statistikken i rapporten www.fhi.no. Requests regarding the statistics can be kan sendes som e-post til [email protected]. forwarded by email to [email protected]. Oslo, mars 2017 Oslo, March 2017 4 Legemiddelstatistikk 2017:1•Folkehelseinstituttet Innhold Forord ..................................................................................................................................................................... 4 Innledning ............................................................................................................................................................... 7 Anatomisk Terapeutisk Kjemisk (ATC) klassifikasjon ............................................................................................. 7 Måleenheter (Definert døgndose (DDD) og Kroner) ............................................................................................... 8 Vurdering og anvendelse av legemiddelstatistikk ................................................................................................. 10 Nordisk statistikk ................................................................................................................................................... 10 Generelle kommentarer til salgsutviklingen .......................................................................................................... 11 Totalomsetningen ......................................................................................................................................... 11 Reseptbelagte legemidler ............................................................................................................................. 11 Reseptfrie legemidler ................................................................................................................................... 11 Legemiddelsalg utenom apotek ................................................................................................................... 12 Omsetning pr legemiddelgruppe .................................................................................................................. 13 Fylkesstatistikk ............................................................................................................................................. 13 Folkemengde etter alder 2012-2016 ..................................................................................................................... 19 Forkortelser ........................................................................................................................................................... 20 Statistikk pr ATC hovedgruppe A Fordøyelsesorganer og stoffskifte ................................................................................................................... 21 B Blod og bloddannende organer ....................................................................................................................... 29 C Hjerte og kretsløp
Recommended publications
  • Kengrexal, INN-Cangrelor Tetrasodium

    Kengrexal, INN-Cangrelor Tetrasodium

    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Kengrexal 50 mg powder for concentrate for solution for injection/infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains cangrelor tetrasodium corresponding to 50 mg cangrelor. After reconstitution 1 mL of concentrate contains 10 mg cangrelor. After dilution 1 mL of solution contains 200 micrograms cangrelor. Excipient with known effect Each vial contains 52.2 mg sorbitol. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for concentrate for solution for injection/infusion. White to off-white lyophilised powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable. 4.2 Posology and method of administration Kengrexal should be administered by a physician experienced in either acute coronary care or in coronary intervention procedures and is intended for specialised use in an acute and hospital setting. Posology The recommended dose of Kengrexal for patients undergoing PCI is a 30 micrograms/kg intravenous bolus followed immediately by 4 micrograms/kg/min intravenous infusion. The bolus and infusion should be initiated prior to the procedure and continued for at least two hours or for the duration of the procedure, whichever is longer. At the discretion of the physician, the infusion may be continued for a total duration of four hours, see section 5.1.
  • Antimicrobial Activity of Cationic

    Antimicrobial Activity of Cationic

    ANTIMICROBIAL ACTIVITY OF CATIONIC ANTISEPTICS IN LAYER-BY-LAYER THIN FILM ASSEMBLIES A Thesis by CHARLENE MYRIAH DVORACEK Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE May 2009 Major Subject: Mechanical Engineering ANTIMICROBIAL ACTIVITY OF CATIONIC ANTISEPTICS IN LAYER-BY-LAYER THIN FILM ASSEMBLIES A Thesis by CHARLENE MYRIAH DVORACEK Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Approved by: Chair of Committee, Jaime Grunlan Committee Members, Michael Benedik Xinghang Zhang Head of Department, Dennis O'Neal May 2009 Major Subject: Mechanical Engineering iii ABSTRACT Antimicrobial Activity of Cationic Antiseptics in Layer-by-Layer Thin Film Assemblies. (May 2009) Charlene Myriah Dvoracek, B.S., Rose-Hulman Institute of Technology Chair of Advisory Committee: Dr. Jaime Grunlan Layer-by-layer (LbL) assembly has proven to be a powerful technique for assembling thin films with a variety of properties including electrochromic, molecular sensing, oxygen barrier, and antimicrobial. LbL involves the deposition of alternating cationic and anionic ingredients from solution, utilizing the electrostatic charges to develop multilayer films. The present work incorporates cationic antimicrobial agents into the positively-charged layers of LbL assemblies. When these thin films are exposed to a humid environment, the antimicrobial molecules readily diffuse out and prevent bacterial growth. The influence of exposure time, testing temperature, secondary ingredients and number of bilayers on antimicrobial efficacy is evaluated here. Additionally, film growth and microstructure are analyzed to better understand the behavior of these films.
  • Reseptregisteret 2013–2017 the Norwegian Prescription Database

    Reseptregisteret 2013–2017 the Norwegian Prescription Database

    LEGEMIDDELSTATISTIKK 2018:2 Reseptregisteret 2013–2017 Tema: Legemidler og eldre The Norwegian Prescription Database 2013–2017 Topic: Drug use in the elderly Reseptregisteret 2013–2017 Tema: Legemidler og eldre The Norwegian Prescription Database 2013–2017 Topic: Drug use in the elderly Christian Berg Hege Salvesen Blix Olaug Fenne Kari Furu Vidar Hjellvik Kari Jansdotter Husabø Irene Litleskare Marit Rønning Solveig Sakshaug Randi Selmer Anne-Johanne Søgaard Sissel Torheim Utgitt av Folkehelseinstituttet/Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Juni 2018 Tittel/Title: Legemiddelstatistikk 2018:2 Reseptregisteret 2013–2017 / The Norwegian Prescription Database 2013–2017 Forfattere/Authors: Christian Berg, redaktør/editor Hege Salvesen Blix Olaug Fenne Kari Furu Vidar Hjellvik Kari Jansdotter Husabø Irene Litleskare Marit Rønning Solveig Sakshaug Randi Selmer Anne-Johanne Søgaard Sissel Torheim Acknowledgement: Julie D. W. Johansen (English text) Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no The report can be downloaded from www.fhi.no Grafisk design omslag: Fete Typer Ombrekking: Houston911 Kontaktinformasjon/Contact information: Folkehelseinstituttet/Norwegian Institute of Public Health Postboks 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN: 978-82-8082-926-9 Sitering/Citation: Berg, C (red), Reseptregisteret 2013–2017 [The Norwegian Prescription Database 2013–2017] Legemiddelstatistikk 2018:2, Oslo, Norge: Folkehelseinstituttet, 2018. Tidligere utgaver / Previous editions: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian Prescription Database 2005–2009.
  • Being Aware of Chlorhexidine Allergy

    Being Aware of Chlorhexidine Allergy

    Being aware of chlorhexidine allergy If you have an immediate allergic reaction to chlorhexidine you may experience symptoms such as: x itching x skin rash (hives) x swelling x anaphylaxis. People who develop anaphylaxis to chlorhexidine may have experienced mild reactions, such as skin rash, to chlorhexidine before. Irritant contact dermatitis or allergic contact dermatitis Chlorhexidine can also cause irritant dermatitis. This is not a true allergic reaction. It is caused by chlorhexidine directly irritating skin and results in rough, dry and scaly Chlorhexidine is an antiseptic. Allergic reactions to skin, sometimes with weeping sores. chlorhexidine are rare but are becoming more common. Chlorhexidine is used in many products both in Chlorhexidine can also cause allergic contact hospitals and in the community. dermatitis. Symptoms look like irritant dermatitis, but the cause of the symptoms is delayed by 12-48 hours Why have I been given this factsheet? after contact with chlorhexidine. You have been given this brochure because you have had a reaction to a medication, a medical dressing Both irritant dermatitis and allergic contact dermatitis or antiseptic. This may or may not be caused by a caused by chlorhexidine are annoying but not chlorhexidine allergy. dangerous. It is important that you are aware of the possibility of an It is recommended that you avoid chlorhexidine if you allergy. experience these responses as some people have gone on to develop immediate allergic reaction to chlorhexidine. Allergic reactions to chlorhexidine Severe allergic reactions to chlorhexidine are rare, but How do I know which products contain they can be serious. Immediate allergic reactions can chlorhexidine? cause anaphlaxis (a very severe allergic reaction which can be life-threatening).
  • Heparin Induced Thrombocytopenia – Adult – Inpatient– Clinical Practice Guideline

    Heparin Induced Thrombocytopenia – Adult – Inpatient– Clinical Practice Guideline

    Heparin Induced Thrombocytopenia – Adult – Inpatient– Clinical Practice Guideline Table of Contents EXECUTIVE SUMMARY ........................................................................................................... 2 SCOPE ...................................................................................................................................... 6 METHODOLOGY ...................................................................................................................... 6 DEFINITIONS (OPTIONAL): ..................................................................................................... 7 INTRODUCTION ....................................................................................................................... 7 RECOMMENDATIONS .............................................................................................................. 7 BENEFITS/HARMS OF IMPLEMENTATION ...........................................................................17 IMPLEMENTATION PLAN AND TOOLS ........................ERROR! BOOKMARK NOT DEFINED. REFERENCES .........................................................................................................................17 APPENDIX A ............................................................................................................................17 Note: Active Table of Contents Click to follow link CPG Contact for Changes: CPG Contact for Content: Name: Philip J Trapskin, PharmD,BCPS Name: Anne E. Rose, PharmD Phone Number: 263-1328 Phone Number:
  • National OTC Medicines List

    National OTC Medicines List

    National OTC Medicines List ‐ DraŌ 01 DRAFT National OTC Medicines List Draft 01 Ministry of Public Health of Lebanon This list was prepared under the guidance of His Excellency Minister Waêl Abou Faour andDRAFT the supervision of the Director General Dr. Walid Ammar. Editors Rita KARAM, Pharm D. PhD. Myriam WATFA, Pharm D Ghassan HAMADEH, MD.CPE FOREWORD According to the French National Agency for Medicines and Health Products Safety (ANSM), Over-the-counter (OTC) drugs are medicines that are accessible to patients in pharmacies, based on criteria set to safeguard patients’ safety. Due to their therapeutic class, these medicines could be dispensed without physician’s intervention for diagnostic, treatment initiation or maintenance purposes. Moreover, their dosage, treatment period and Package Insert Leaflet should be suitable for OTC classification. The packaging size should be in accordance with the dosage and treatment period. According to ArticleDRAFT 43 of the Law No.367 issued in 1994 related to the pharmacy practice, and the amendment of Articles 46 and 47 by Law No.91 issued in 2010, pharmacists do not have the right to dispense any medicine that is not requested by a unified prescription, unless the medicine is mentioned in a list which is established by pharmacists and physicians’ syndicates. In this regard, the Ministry of Public Health (MoPH) developed the National OTC Medicines List, and presentedit in a scientific, objective, reliable, and accessible listing. The OTC List was developed by a team of pharmacists and physicians from the Ministry of Public Health (MoPH). In order to ensure a safe and effective self- medicationat the pharmacy level, several pharmaceutical categories (e.g.
  • Anticoagulation Dosing Guideline for Adult COVID-19 Patients

    Anticoagulation Dosing Guideline for Adult COVID-19 Patients

    Anticoagulation Dosing Guideline for Adult COVID-19 Patients Enoxaparin is the preferred first line anticoagulant for patients diagnosed with COVID-19. The incidence of HIT with enoxaparin is less than 1%. VTE Prophylaxis: VTE prophylaxis will be considered for COVID-19 patients who are low risk. Low risk COVID-19 patient 1. Not receiving mechanical ventilation 2. D-Dimer < 6 mg/L 3. ESRD on iHD without clotting Kidney Function BMI (kg/m2) Dosing of Enoxaparin Concern for HIT or LMWH Failure CrCL ≥ 30 mL/min 18.5-39.9 30mg SUBQ Q12H Consult Hematology 40-49.9 40mg SUBQ Q12H ≥ 50 60mg SUBQ Q12H CrCL < 30 mL/min 18.5-39.9 30mg SUBQ Q24H Consult Hematology OR ≥ 40 40mg SUBQ Q24H ESRD/AKI on RRT Special Population: < 18.5 (or weight < 50kg) Heparin 2500 SUBQ Q8H Consult Hematology *Contraindications: Platelets < 25 K/uL or Fibrinogen < 50 mg/dL or active bleeding Therapeutic anticoagulation Therapeutic anticoagulation will be considered for COVID-19 patients who are considered high risk or diagnosed with an acute VTE. High risk COVID-19 patient (for all hospitalized patients): Receiving mechanical ventilation AND D-dimer > 6 mg/L OR Acute kidney injury (Scr increase 0.3 mg/dL above baseline) +/- CVVHD/AVVHD/SLED or IHD with clotting Anti-Xa level goals for enoxaparin therapy (when indicated): 1. Therapeutic peak LMWH level (Drawn 4 hours after 3rd dose): 0.6-1 anti-Xa units/mL 2. Therapeutic trough LMWH level (Drawn 1 hour prior to 3rd dose): < 0.5 anti-Xa units/mL Kidney Function BMI Dosing of Enoxaparin Concern for HIT or (kg/m2) LMWH
  • Transition of Anticoagulants 2019

    Transition of Anticoagulants 2019

    Transition of Anticoagulants 2019 Van Hellerslia, PharmD, BCPS, CACP, Brand Generic Clinical Assistant Professor of Pharmacy Practice, Angiomax bivalirudin Temple University School of Pharmacy, Philadelphia, PA Arixtra fondaparinux Bevyxxa betrixaban Pallav Mehta, MD, Assistant Professor of Medicine, Coumadin warfarin Division of Hematology/Oncology, Eliquis apixaban MD Anderson Cancer Center at Cooper, Camden, NJ Fragmin dalteparin Lovenox enoxaparin Reviewer: Kelly Rudd, PharmD, BCPS, CACP, Pradaxa dabigatran Clinical Specialist, Anticoagulation, Bassett Medical Center, Savaysa edoxaban Cooperstown, NY Xarelto rivaroxaban From To Action Apixaban Argatroban/ Wait 12 hours after last dose of apixaban to initiate parenteral anticoagulant. In cases of Bivalirudin/ high bleeding risk, consider omitting initial bolus when transitioning to heparin infusion. Enoxaparin/ Dalteparin/ Fondaparinux/ Heparin Apixaban Warfarin When going from apixaban to warfarin, consider the use of parenteral anticoagulation as a bridge (eg, start heparin infusion or therapeutic enoxaparin AND warfarin 12 hours after last dose of apixaban and discontinue parenteral anticoagulant when INR is therapeutic). Apixaban affects INR so that initial INR measurements during the transition may not be useful for determining the appropriate dose of warfarin. Apixaban Betrixaban, Wait 12 hours from last dose of apixaban to initiate betrixaban, dabigatran, edoxaban, or Dabigatran, rivaroxaban. Edoxaban, or Rivaroxaban Argatroban Apixaban, Start apixaban, betrixaban, dabigatran,
  • List Item Cetrimide: Summary Report

    List Item Cetrimide: Summary Report

    The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/073/96-FINAL March 1996 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS CETRIMIDE SUMMARY REPORT 1. Cetrimide (CAS 8044-71-1) is a quaternary ammonium antiseptic and surfactant. It consists mostly of trimethyltetradecylammonium bromide (CAS 1119-97-7; also known as tetradonium bromide) with smaller amounts of dodecyltrimethylammonium bromide (CAS 1119-94-4; also known as DTAB) and hexadecyltrimethylammonium bromide (CAS 57-09-0). The European Pharmacopoeia requires that cetrimide should contain at least 96% but no more than 101.0% alkyltrimethylammonium bromides. 2. Historically, the name cetrimide was used for a material consisting of predominantly hexadecyltrimethylammonium bromide, (CAS 57-09-0; also known as cetrimonium bromide, CTAB, and cetyltrimethylammonium bromide), together with smaller amounts of analogous alkyltrimethylammonium bromides. Some of the safety studies were carried out using this "cetrimide" rather than the cetrimide currently specified in the Europeam Pharmacopoeia. 3. In veterinary medicine, cetrimide is used as a topical antiseptic at concentrations of up to 2%. It is also used as an excipient in an injectable antibiotic formulation intended for use in cattle, sheep and pigs. When used as excipient, the concentration of cetrimide in the formulation is around 0.25 mg/ml, resulting in a dose of approximately 0.01 mg/kg bw of cetrimide in the target species. 4. In aqueous solution, cetrimide dissociates to a biologically-active cation and an inactive anion. Cetrimide is inactive towards bacterial spores, it is effective against some viruses and has variable anti-fungal activity. The cation is also responsible for the surfactant activity.
  • Povidone-Iodine (Topical)

    Povidone-Iodine (Topical)

    PATIENT & CAREGIVER EDUCATION Povidone-Iodine (Topical) This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Aplicare Povidone-Iodine Scrub [OTC] [DSC]; Aplicare Povidone-Iodine [OTC] [DSC]; Betadine Antiseptic Dry Powder [OTC]; Betadine Antiseptic Gargle [OTC]; Betadine Antiseptic Rinse [OTC]; Betadine Antiseptic [OTC]; Betadine Skin Cleanser [OTC] [DSC]; Betadine Surgical Scrub [OTC]; Betadine Swabsticks [OTC]; Betadine [OTC]; Clorox Nasal Antiseptic [OTC] [DSC]; ExCel AP [OTC] [DSC]; First Aid Antiseptic [OTC]; NuPrep 5% Povidone-Iodine [OTC] [DSC]; PVP Prep [OTC] [DSC]; PVP Scrub [OTC] [DSC]; Scrub Care Povidone-iodine [OTC]; Summers Eve Disp Medicated [OTC] What is this drug used for? All skin products: It is used to treat or prevent bacterial infections. It may be given to your child for other reasons. Talk with the doctor. All vaginal products: It is used to treat vaginal irritation, itching, and soreness. Throat gargle: It is used to treat a sore throat. Povidone-Iodine (Topical) 1/7 What do I need to tell the doctor BEFORE my child takes this drug? All products: If your child is allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell the doctor about the allergy and what signs your child had. If your child is pregnant or breast-feeding a baby: If your child is pregnant or may be pregnant. Some forms of this drug are not for use during pregnancy. Talk with the doctor if your child is breast-feeding a baby or plans to breast- feed a baby.
  • Antithrombotic Agents in the Management of Sepsis

    Antithrombotic Agents in the Management of Sepsis

    Antithrombotic Agents in the Management of Sepsis !"#$ Loyola University Medical Center, Maywood, Illinois-60153, USA ABSTRACT Sepsis, a systemic inflammatory syndrome, is a response to infection and when associated with mul- tiple organ dysfunction is termed, severe sepsis. It remains a leading cause of mortality in the critically ill. The response to the invading bacteria may be considered as a balance between proinflammatory and antiinflammatory reaction. While an inadequate proinflammatory reaction and a strong antiinflammatory response could lead to overwhelming infection and death of the patient, a strong and uncontrolled pro- inflammatory response, manifested by the release of proinflammatory mediators may lead to microvas- cular thrombosis and multiple organ failure. Endotoxin triggers sepsis by releasing various mediators inc- luding tumor necrosis factor-alpha and interleukin-1(IL-1). These cytokines activate the complement and coagulation systems, release adhesion molecules, prostaglandins, leukotrienes, reactive oxygen speci- es and nitric oxide (NO). Other mediators involved in the sepsis syndrome include IL-1, IL-6 and IL-8; arachidonic acid metabolites; platelet activating factor (PAF); histamine; bradykinin; angiotensin; comp- lement components and vasoactive intestinal peptide. These proinflammatory responses are counterac- ted by IL-10. Most of the trials targeting the different mediators of proinflammatory response have failed due a lack of correct definition of sepsis. Understanding the exact pathophysiology of the disease will enable better treatment options. Targeting the coagulation system with various anticoagulant agents inc- luding antithrombin, activated protein C (APC), tissue factor pathway inhibitor (TFPI) is a rational appro- ach. Many clinical trials have been conducted to evaluate these agents in severe sepsis.
  • Legemiddelforbruket I Norge 2014–2018 Drug Consumption in Norway 2014–2018

    Legemiddelforbruket I Norge 2014–2018 Drug Consumption in Norway 2014–2018

    LEGEMIDDELSTATISTIKK 2019:1 Legemiddelforbruket i Norge 2014–2018 Drug Consumption in Norway 2014–2018 Legemiddelforbruket i Norge 2014–2018 Drug Consumption in Norway 2014–2018 Solveig Sakshaug Kristine Olsen Christian Berg Hege Salvesen Blix Live Storehagen Dansie Irene Litleskare Tove Granum Utgitt av Folkehelseinstituttet/Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Mai 2019 Tittel/Title: Legemiddelstatistikk 2019:1 Legemiddelforbruket i Norge 2014–2018/Drug Consumption in Norway 2014–2018 Forfattere/Authors: Solveig Sakshaug (redaktør) Kristine Olsen Christian Berg Hege Salvesen Blix Live Storehagen Dansie Irene Litleskare Tove Granum Bestilling: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no The report is only available as pdf from www.fhi.no Grafisk design omslag: Fete Typer Kontaktinformasjon/Contact information: Folkehelseinstituttet/Norwegian Institute of Public Health P.O.Box 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN:1890-9647 ISBN elektronisk utgave: 978-82-8406-011-8 Sitering/Citation: Sakshaug, S (red), Legemiddelforbruket i Norge 2014–2018 [Drug Consumption in Norway 2014–2018], Legemiddelstatistikk 2019:1, Oslo: Folkehelseinstituttet, 2019. Tidligere utgaver/Previous editions: 1977: Legemiddelforbruket i Norge 1974–1976 1978: Legemiddelforbruket i Norge 1975–1977 1980: Legemiddelforbruket i Norge 1975–1979 1981: Legemiddelforbruket i Norge 1980 1982: Legemiddelforbruket i Norge 1977–1981 1984: Legemiddelforbruket